✦ LIBER ✦

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ Scribed by P. P. Tak; P. J. Mease; M. C. Genovese; J. Kremer; B. Haraoui; Y. Tanaka; C. O. Bingham III; A. Ashrafzadeh; H. Travers; S. Safa-Leathers; S. Kumar; W. Dummer

Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 199 KB
Volume: 64
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.33353

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and efficacy of ocrelizumab in pa

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial

✍ W. Rigby; H.-P. Tony; K. Oelke; B. Combe; A. Laster; C. A. von Muhlen; E. Fishel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB 👁 1 views

Golimumab, a new human anti–tumor necros

Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Erratum: Golimumab, a new human anti–tum

Erratum: Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight–week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study

✍ Joel Kremer; Christopher Ritchlin; Alan Mendelsohn; Daniel Baker; Lilianne Kim; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 1 views

Rituximab for rheumatoid arthritis refra

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

✍ Stanley B. Cohen; Paul Emery; Maria W. Greenwald; Maxime Dougados; Richard A. Fu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 1 views

Atacicept in patients with rheumatoid ar

Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: Results of a phase II, randomized, placebo-controlled, dose-finding trial

✍ M. C. Genovese; N. Kinnman; G. de La Bourdonnaye; C. Pena Rossi; P. P. Tak 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 242 KB 👁 2 views

Tocilizumab inhibits structural joint da

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year

✍ Joel M. Kremer; Ricardo Blanco; Marek Brzosko; Ruben Burgos-Vargas; Anne-Marie H 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 233 KB 👁 2 views